vs

Side-by-side financial comparison of BIOLIFE SOLUTIONS INC (BLFS) and Ceribell, Inc. (CBLL). Click either name above to swap in a different company.

Ceribell, Inc. is the larger business by last-quarter revenue ($24.8M vs $18.8M, roughly 1.3× BIOLIFE SOLUTIONS INC). BIOLIFE SOLUTIONS INC runs the higher net margin — 58.9% vs -54.6%, a 113.5% gap on every dollar of revenue.

Biolife Solutions Inc. develops, manufactures and distributes specialized biopreservation products and cold chain management solutions for the cell and gene therapy, biopharmaceutical and regenerative medicine industries. It offers cryopreservation media, automated thawing systems, and temperature monitoring tools, serving biotech firms, research institutions and clinical labs globally.

Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.

BLFS vs CBLL — Head-to-Head

Bigger by revenue
CBLL
CBLL
1.3× larger
CBLL
$24.8M
$18.8M
BLFS
Higher net margin
BLFS
BLFS
113.5% more per $
BLFS
58.9%
-54.6%
CBLL

Income Statement — Q4 2025 vs Q4 2025

Metric
BLFS
BLFS
CBLL
CBLL
Revenue
$18.8M
$24.8M
Net Profit
$11.1M
$-13.5M
Gross Margin
87.3%
Operating Margin
7.2%
-58.9%
Net Margin
58.9%
-54.6%
Revenue YoY
24.3%
Net Profit YoY
-11.1%
EPS (diluted)
$0.23
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLFS
BLFS
CBLL
CBLL
Q4 25
$18.8M
$24.8M
Q3 25
$28.1M
$22.6M
Q2 25
$25.4M
$21.2M
Q1 25
$23.9M
$20.5M
Q4 24
$15.1M
Q3 24
$21.4M
$17.2M
Q2 24
$19.7M
Q1 24
$18.4M
Net Profit
BLFS
BLFS
CBLL
CBLL
Q4 25
$11.1M
$-13.5M
Q3 25
$621.0K
$-13.5M
Q2 25
$-15.8M
$-13.6M
Q1 25
$-448.0K
$-12.8M
Q4 24
$12.5M
Q3 24
$-1.7M
$-10.4M
Q2 24
$-20.7M
Q1 24
$-10.2M
Gross Margin
BLFS
BLFS
CBLL
CBLL
Q4 25
87.3%
Q3 25
88.3%
Q2 25
88.1%
Q1 25
87.9%
Q4 24
Q3 24
87.3%
Q2 24
Q1 24
Operating Margin
BLFS
BLFS
CBLL
CBLL
Q4 25
7.2%
-58.9%
Q3 25
-0.3%
-64.8%
Q2 25
-65.5%
-70.5%
Q1 25
-5.1%
-69.3%
Q4 24
3.6%
Q3 24
-2.0%
-57.8%
Q2 24
-6.6%
Q1 24
-17.9%
Net Margin
BLFS
BLFS
CBLL
CBLL
Q4 25
58.9%
-54.6%
Q3 25
2.2%
-59.6%
Q2 25
-62.3%
-64.4%
Q1 25
-1.9%
-62.4%
Q4 24
82.5%
Q3 24
-8.0%
-60.6%
Q2 24
-105.1%
Q1 24
-55.4%
EPS (diluted)
BLFS
BLFS
CBLL
CBLL
Q4 25
$0.23
$-0.35
Q3 25
$0.01
$-0.37
Q2 25
$-0.33
$-0.38
Q1 25
$-0.01
$-0.36
Q4 24
$0.27
Q3 24
$-0.04
$-1.85
Q2 24
$-0.45
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLFS
BLFS
CBLL
CBLL
Cash + ST InvestmentsLiquidity on hand
$33.0M
$159.3M
Total DebtLower is stronger
$5.0M
Stockholders' EquityBook value
$371.9M
$155.3M
Total Assets
$405.9M
$195.8M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLFS
BLFS
CBLL
CBLL
Q4 25
$33.0M
$159.3M
Q3 25
$29.5M
$168.5M
Q2 25
$31.9M
$177.4M
Q1 25
$66.9M
$182.7M
Q4 24
$91.5M
Q3 24
$24.0M
$14.1M
Q2 24
$22.0M
Q1 24
$29.7M
Total Debt
BLFS
BLFS
CBLL
CBLL
Q4 25
$5.0M
Q3 25
$7.5M
Q2 25
$10.1M
Q1 25
$12.9M
Q4 24
$15.9M
Q3 24
$20.1M
Q2 24
$21.1M
Q1 24
$24.3M
Stockholders' Equity
BLFS
BLFS
CBLL
CBLL
Q4 25
$371.9M
$155.3M
Q3 25
$353.7M
$164.1M
Q2 25
$347.2M
$172.2M
Q1 25
$352.6M
$180.9M
Q4 24
$348.9M
Q3 24
$325.5M
$-136.0M
Q2 24
$321.4M
Q1 24
$333.4M
Total Assets
BLFS
BLFS
CBLL
CBLL
Q4 25
$405.9M
$195.8M
Q3 25
$392.1M
$199.5M
Q2 25
$387.2M
$207.7M
Q1 25
$395.1M
$213.5M
Q4 24
$399.5M
Q3 24
$381.7M
$47.1M
Q2 24
$375.0M
Q1 24
$401.6M
Debt / Equity
BLFS
BLFS
CBLL
CBLL
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.04×
Q4 24
0.05×
Q3 24
0.06×
Q2 24
0.07×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLFS
BLFS
CBLL
CBLL
Operating Cash FlowLast quarter
$4.9M
$-10.8M
Free Cash FlowOCF − Capex
$-11.0M
FCF MarginFCF / Revenue
-44.2%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
0.44×
TTM Free Cash FlowTrailing 4 quarters
$-41.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLFS
BLFS
CBLL
CBLL
Q4 25
$4.9M
$-10.8M
Q3 25
$6.1M
$-11.1M
Q2 25
$7.4M
$-7.5M
Q1 25
$1.7M
$-11.4M
Q4 24
$1.6M
Q3 24
$4.8M
Q2 24
$6.5M
Q1 24
$-4.5M
Free Cash Flow
BLFS
BLFS
CBLL
CBLL
Q4 25
$-11.0M
Q3 25
$-11.5M
Q2 25
$-7.6M
Q1 25
$-11.6M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
BLFS
BLFS
CBLL
CBLL
Q4 25
-44.2%
Q3 25
-50.8%
Q2 25
-35.9%
Q1 25
-56.4%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
BLFS
BLFS
CBLL
CBLL
Q4 25
0.7%
Q3 25
1.6%
Q2 25
0.3%
Q1 25
0.7%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
BLFS
BLFS
CBLL
CBLL
Q4 25
0.44×
Q3 25
9.83×
Q2 25
Q1 25
Q4 24
0.13×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLFS
BLFS

Segment breakdown not available.

CBLL
CBLL

Products$18.8M76%
Subscription$6.0M24%

Related Comparisons